Abbott Laboratories (ABT) Faces Class-Action Lawsuit Over PediaSure
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowA federal judge ruled that Abbott Laboratories (ABT) must face a class-action lawsuit regarding allegations it misled consumers about PediaSure Grow & Gain drinks being 'clinically proven' for children's growth. The lawsuit claims the marketing could mislead consumers into interpreting growth as height gain, while using labels suggesting weight gain. Plaintiff Joanne Noriega alleges her grandson remained short after a year of daily use. Abbott maintains its labeling is appropriate and evidence-based, stating PediaSure supports children's growth and development.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Abbott Laboratories (ABT)
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, and nutrition.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABT news
- Abbott Labs (ABT) to Report Q2 Earnings on July 16, Growth Insights
- Adeptus Biotechnologies Stock Rating Maintained by BTIG
- Abbott Laboratories (ABT) Director Daniel Starks Buys $926,537 in Shares
- Abbott Labs (ABT) stock price target cut to $120 by Benchmark
- Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
